Product Comparison


No Image

Schering Plough 00052060202
McKesson # 1166153 706308
Description Bladder Cancer Treatment Valrubicin 40 mg / mL Injection Single-Dose Vial 5 mL TICE® BCG Bladder Cancer Treatment Bacillus Calmette-Guérin (BCG) Live 50 mg Injection Single-Dose Vial 2 mL
Manufacturer # 2420101010400052060202
Brand  TICE® BCG
Manufacturer Hikma Specialty USA (Leucadia)Schering Plough
    Log In to Order   Log In to Order


Country of Origin UnknownUnited States
Generic Drug Code 9417514103
Generic Drug Name ValrubicinBacillus Calmette-Guérin (BCG) Live
NDC Number 2420101010400052060202
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 days
Strength 40 mg / mL50 mg
UNSPSC Code 5128181051201647
Volume 5 mL2 mL
Application Bladder Cancer TreatmentBladder Cancer Treatment
Container Type Single-Dose VialSingle-Dose Vial
Dosage Form InjectionInjection
Storage Requirements Requires RefrigerationRequires Refrigeration
Type IntravesicalIntravesical
Features and Benefits
  • Do not administer without diluting
  • For Intravesical use only
  • Not for intramuscular or intravenous use
  • The dose for the intravesical treatment of carcinoma in situ and for the prophylaxis of recurrent papillary tumors consists of one vial of TICE® BCG suspended in 50 ml preservative-free saline
  • Intravesical TICE® BCG has been used as a therapy for, and prophylaxis against, recurrent tumors in patients with carcinoma in situ (CIS) of the urinary bladder, and to prevent recurrence of Stage TaT1 papillary tumors of the bladder at high risk of recurrence
  • BCG LIVE (TICE® BCG) is not a vaccine for the prevention of cancer
  • Reconstituted TICE® BCG should be kept refrigerated (2-8° C), protected from exposure to direct sunlight, and used within 2 hours
  • Store Refrigerated at 2 to 8 degrees C (36 to 46 degrees F)